The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density

BMC Genetics

Volumn 6, Issue , 2005, Pages

  VanNess, Sidney H ^a   Owens, Michael J ^a   Kilts, Clinton D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE; DNA POLYMERASE; RECOMBINASE; SLC6A3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING ASSAY; CELL STRAIN HEK293; CONTROLLED STUDY; DOWNSTREAM PROCESSING; GENE CONSTRUCT; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PROMOTER REGION; PROTEIN EXPRESSION; RECOMBINANT DNA TECHNOLOGY; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; VARIABLE NUMBER OF TANDEM REPEAT; ATTENTION DEFICIT DISORDER; BINDING COMPETITION; CELL LINE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC ENGINEERING; GENETICS; METABOLISM; PHENOTYPE; PHYSIOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BINDING, COMPETITIVE; CELL LINE; DNA NUCLEOTIDYLTRANSFERASES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC VECTORS; GENOTYPE; HUMANS; MINISATELLITE REPEATS; PHENOTYPE; POLYMORPHISM, GENETIC; TRANSFECTION;

EID: 28844437326     PISSN: 14712156     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/1471-2156-6-55     Document Type: Article

References (51)

1. Kawarai T, Kawakami H, Yamamura Y, Nakamura S: Structure and organization of the gene encoding human dopamine transporter. Gene 1997, 195(1):11-18.
2. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG: Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992, 42(3):383-390.
3. Vandenbergh DJ, Persico AM, Uhl GR: A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Research Molecular Brain Research 1992, 15(1-2):161-166.
4. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992, 14(4):1104-1106.
5. Mitchell RJ, Howlett S, Earl L, White NG, McComb J, Schanfield MS, Briceno I, Papiha SS, Osipova L, Livshits G et al: Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations. Human Biology 2000, 72(2):295-304.
6. Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI: Population genetic study of the human dopamine transporter gene (DAT1). Genetic Epidemiology 1995,12(3):303-308.
7. Kang AM, Palmatier MA, Kidd KK: Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 1999, 46(2):151-160.
8. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G: Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991, 254(5031):576-578.
9. Wu X, Gu HH: Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 1999, 233(1-2): 163-170.
10. Miller GM, De La Garza RD, 2nd, Novak MA, Madras BK: Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. Molecular Psychiatry 2001, 6(1):50-58.
11. Conne B, Stutz A, Vassalli JD: The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med 2000, 6(6):637-641.
12. Nakamura Y, Koyama K, Matsushima M: VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet 1998, 43(3):149-152.
13. Fuke S, Sasagawa N, Ishiura. S: Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3′ non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J Biochem (Tokyo) 2005, 137(2):205-216.
14. Mignone F, Gissi C, Liuni S, Pesole G: Untranslated regions of mRNAs. Genome Biol 2002, 3(3):REVIEWS0004.
15. Cook EH, Jr., Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL: Association of attention-deficit disorder and the dopamine transporter gene. American Journal of Human Genetics 1995, 56(4):993-998.
16. Daly G, Hawi Z, Fitzgerald M, Gill M: Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Molecular Psychiatry 1999, 4(2):192-196.
17. Barr CL, Xu C, Kroft J, Feng Y, Wigg K, Zai G, Tannock R, Schachar R, Malone M, Roberts W et al: Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biological Psychiatry 2001, 49(4):333-339.
18. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M: Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Molecular Psychiatry 1997, 2(4):311-313.
19. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C: Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. American Journal of Human Genetics 1998, 63(6):1767-1776.
20. Chen CK, Chen SL, Mill J, Huang YS, Lin SK, Curran S, Purcell S, Sham P, Asherson P: The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol Psychiatry 2003, 8(4):393-396.
21. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S: The VNTR polymorphisin of the human dopamine transporter (DAT1) gene affects gene expression. The Pharmacogenomics Journal 2001, 1:152-156.
22. Inoue-Murayama M, Adachi S, Mishima N, Mitani H, Takenaka O, Terao K, Hayasaka I, Ito S, Murayama Y: Variation of variable number of tandem repeat sequences in the 3′-untranslated region of primate dopamine transporter genes that affects reporter gene expression. Neurosci Lett 2002, 334(3):206-210.
23. Michelhaugh SK: The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. Journal of Neurochemistry 2001, 79(5):1033-1038.
24. Greenwood TA, Kelsoe JR: Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003, 82(5):511-520.
25. Mill J, Asherson P, Craig I, D'Souza UM: Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005, 6(1):3.
26. Miller GM, Madras BK: Polymorphisms; in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002, 7(1):44-55.
27. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB, Laruelle M: The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001, 24(5):553-560.
28. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J: Prediction of dopamine transporter binding availability by genotype: a preliminary report. American Journal of Psychiatry 2000, 157(10):1700-1703.
29. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000, 22(2):133-139.
30. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J: Increased Dopamine Transporter Availability Associated with the 9-Repeat Allele of the SLC6A3 Gene. Journal of Nuclear Medicine 2005, 46(5):745-751.
31. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarron M, O'Donnell D, Fitzgerald M, Gill M: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 2003, 121B(1):50-54.
32. Winsberg BG, Comings DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response [see comments]. Journal of the American Academy of Child & Adolescent Psychiatry 1999, 38(12):1474-1477.
33. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005, 30(7):1374-1382.
34. Cheon KA, Ryu YH, Kim JW, Cho DY: The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 2005, 15(1):95-101.
35. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M et al: Dopamine genes and ADHD. Neuroscience & Biobehavioral Reviews 2000, 24(1):21-25.
36. Sauer B: Site-specific recombination: developments and applications. Curr Opin Biotechnol 1994, 5(5):521-527.
37. O'Gorman S, Fox DT, Wahl GM: Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 1991, 251(4999):1351-1355.
38. Zhang K, Kurachi S, Kurachi K: Limitation in use of heterologous reporter genes for gene promoter analysis. Silencer activity associated with the cloramphenicol acetyltransferase reporter gene. J Biol Chem 2003, 278(7):4826-4830.
39. Jones JR, Shelton KD, Magnuson MA: Strategies for the use of site-specific recombinases in genome engineering. Methods Mol Med 2004, 103:245-258.
40. Kolb AF: Genome engineering using site-specific recombinases. Cloning Stem Cells 2002, 4(1):65-80.
41. Wirth D, Hauser H: Flp-mediated integration of expression cassettes into FRT-tagged chromosomal loci in mammalian cells. Methods Mol Biol 2004, 267:467-476.
42. Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, Neumeyer JL: [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol 1999, 385(2-3):291-294.
43. Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM: Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 2003, 44(6):855-861.
44. Du L, Faludi G, Palkovits M, Demeter E, Bakish D, Lapierre YD, Sotonyi P, Hrdina PD: Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry 1999, 46(2):196-201.
45. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ et al: 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nuclear Medicine & Biology 2000, 27(1):1-12.
46. Melikian HE, Buckley KM: Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 1999, 19(18):7699-7710.
47. Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, Niznik HB: Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 1998, 30(1):79-87.
48. Loder MK, Melikian HE: The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell fines. J Biol Chem 2003, 278(24):22168-22174.
49. Nicola SM, Woodward Hopf F, Hjelmstad GO: Contrast enhancement: a physiological effect of striatal dopamine? Cell Tissue Res 2004, 318(1):93-106.
50. O'Donnell P: Dopamine gating of forebrain neural ensembles. Eur J Neurosci 2003, 17(3):429-435.
51. Dymecki SM: Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc Natl Acad Sci U S A 1996, 93(12):6191-6196.